Carpal Tunnel Syndrome (CTS)NCT07371221
Ultrasound-Guided Dextrose Hydrodissection of the Median Nerve
A study testing Ultrasound-Guided Median Nerve Hydrodissection with 5% Dextrose in people with Carpal Tunnel Syndrome (CTS), run by Dr. Nafiz Korez Sincan State Hospital at 1 site in Turkey (Türkiye).
Trial summary
The goal of this clinical trial is to evaluate the clinical and ultrasonographic outcomes of ultrasound-guided median nerve hydrodissection with 5% dextrose in patients with mild and moderate carpal tunnel syndrome. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Carpal Tunnel Syndrome (CTS)
- What is being tested?
- Ultrasound-Guided Median Nerve Hydrodissection with 5% Dextrose
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 37 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 17 Jun 2024to 26 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 18 and 65 years
- Electrophysiologically confirmed mild to moderate CTS on electroneuromyography (ENMG)
- Paresthesia or dysesthesia that worsens at night or with repetitive wrist movement
- Presence of at least one of the following clinical findings:
- Numbness in the median nerve distribution
- Decreased hand strength or thenar muscle weakness
- Positive Phalen's test and/or Tinel's sign
- Pain intensity of ≥3 on the Visual Analog Scale (VAS)
Who cannot join
- Previous carpal tunnel surgery
- Severe CTS on ENMG
- Polyneuropathy
- Pregnancy
- Injections in the same area within the last 3 months
- Peripheral nerve injury, thoracic outlet syndrome, cervical radiculopathy, brachial plexopathy
Show all 9Show fewer
- Traumatic hand injury in the last 2 years
- Inflammatory rheumatological disease
- Thyroid and autoimmune disease
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Dr. Nafiz Korez Sincan State Hospital
Ankara, Ankara, 06340
About this study
Official title: Ultrasound-Guided Nerve Hydrodissection With 5% Dextrose in Carpal Tunnel Syndrome: A Prospective Study
The goal of this clinical trial is to evaluate the clinical and ultrasonographic outcomes of ultrasound-guided median nerve hydrodissection with 5% dextrose in patients with mild and moderate carpal tunnel syndrome.
The main questions it aims to answer are:
Read more
- Does ultrasound-guided dextrose hydrodissection improve pain and functional status in patients with carpal tunnel syndrome?
- Does this procedure lead to changes in ultrasonographic parameters of the median nerve?
- Is ultrasound-guided dextrose hydrodissection a safe procedure in this patient population?
Participants will:
- Undergo a single session of ultrasound-guided median nerve hydrodissection with 5% dextrose
- Be evaluated before the procedure and at 1-month and 3-month follow-up visits using clinical outcome measures and ultrasound assessment
- Be monitored for any procedure-related adverse events
Read the detailed description
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy of the upper extremity and is caused by compression of the median nerve within the carpal tunnel. Conservative treatment options are commonly preferred in patients with mild to moderate CTS. Ultrasound-guided interventions have gained increasing attention due to their ability to provide real-time visualization of anatomical structures and improve procedural accuracy and safety.
Ultrasound-guided median nerve hydrodissection is a minimally invasive technique that aims to mechanically separate the median nerve from surrounding tissues within the carpal tunnel, potentially reducing nerve compression and improving nerve mobility. The use of 5% dextrose solution has been suggested to provide both mechanical and potential neuromodulatory effects, which may contribute to symptom relief.
In this prospective study, patients diagnosed with mild and moderate CTS undergo ultrasound-guided median nerve hydrodissection using 5% dextrose. All procedures are performed under aseptic conditions by experienced physicians trained in ultrasound-guided interventions. A high-frequency linear ultrasound transducer is used to visualize the median nerve and surrounding anatomical structures at the level of the carpal tunnel. Hydrodissection is performed using an in-plane technique, which allows for continuous visualization of the needle and injectate during the procedure.
Participants receive a single-session ultrasound-guided hydrodissection, during which the injectate is administered to separate the median nerve from adjacent connective tissues. The procedure is conducted according to a standardized protocol to ensure consistency across all participants.
Clinical and ultrasonographic assessments are performed at baseline, and at 1-month and 3-month follow-up visits after the ultrasound-guided injection. Patients are monitored for any procedure-related adverse events throughout the study period. The study aims to evaluate changes in clinical symptoms and ultrasound findings following the intervention, as well as to assess the safety profile of ultrasound-guided dextrose hydrodissection in patients with mild and moderate CTS.
- Conditions
- Carpal Tunnel Syndrome (CTS)
- Being tested
- Ultrasound-Guided Median Nerve Hydrodissection with 5% Dextrose
- Keywords
- carpal tunnel syndrome, hydrodissection, Microvascular imaging, ultrasound guided injection, median nerve
- Medical subject headings
- Carpal Tunnel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound-Guided Median Nerve Hydrodissection with 5% DextroseProcedure or surgery
This intervention consists of a single-session ultrasound-guided hydrodissection of the median nerve using 5% dextrose solution in patients with mild and moderate carpal tunnel syndrome. The procedure is performed under aseptic conditions by trained physicians using a high-frequency linear ultrasound transducer. Real-time in-plane imaging is used to visualize the median nerve and surrounding structures, and the injectate is administered via an ulnar approach to mechanically separate the median nerve from adjacent connective tissues within the carpal tunnel. Participants are monitored for any procedure-related adverse events during and after the intervention.
| Study group | Role | What they receive |
|---|---|---|
| Ultrasound-Guided Dextrose Median Nerve Hydrodissection | Experimental | Participants in this arm undergo a single session of ultrasound-guided median nerve hydrodissection using 5% dextrose solution. The procedure is performed under aseptic conditions with real-time ultrasound guidance to visualize the median nerve and surrounding anatomical structures within the carpal tunnel. The injectate is administered to mechanically separate the median nerve from adjacent tissues. Receives: Procedure: Ultrasound-Guided Median Nerve Hydrodissection with 5% Dextrose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Visual Analog Scale
The severity of pain in the fingers over the past week was measured using a 10-cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Measured: Baseline, 1 month and 3 months
Secondary outcomes (3)
Change in Vascularity Index of the Median Nerve
The Vascularity Index (VI) is a quantitative ultrasonographic measure of intraneural microvascularity of the median nerve. The VI is calculated as a percentage value ranging from 0 to 100, representing the proportion of pixels containing vascular signals within a predefined rectangular region of interest (ROI). Higher VI values indicate increased intraneural microvascularity and represent a worse disease-related finding.
Measured: Baseline, 1 month and 3 months
Change in median nerve cross-sectional area
The cross-sectional area (CSA) of the median nerve was evaluated using ultrasonography by measuring the nerve at the thickest visible level within the carpal tunnel.
Measured: Baseline, 1 month and 3 months
Change in Boston Carpal Tunnel Questionnaire
The Boston Carpal Tunnel Questionnaire (BCTQ) consists of two subscales: the Symptom Severity Scale (11 items), which assesses the intensity of CTS-related symptoms, and the Functional Status Scale (8 items), which evaluates the degree of difficulty in performing daily activities. Each item is scored on a 5-point scale ranging from 1 to 5, with higher scores indicating greater symptom severity in the Symptom Severity Scale and greater functional impairment in the Functional Status Scale.
Measured: Baseline, 1 month and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2026
- Study start17 Jun 2024
- Primary completion26 Jun 2025
- Study completion26 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carpal Tunnel Syndrome (CTS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single-arm, prospective, non-randomized interventional study. All participants receive ultrasound-guided median nerve hydrodissection with 5% dextrose, and outcomes are measured before and after the intervention.
- Masking
- None (open label)
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr. Nafiz Korez Sincan State Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Sevgi Esra Ozdemir Tekes, Dr. Nafiz Korez Sincan State Hospital
- Investigators
- Suheyla Dal Erdogan, Medical Doctor, Study chair, Dr. Nafiz Korez Sincan State HospitalSevgi Esra Ozdemir Tekes, Principal investigator, Dr. Nafiz Korez Sincan State Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07371221
- Sponsor's protocol ID
- 2024-KAEK-09
- Status last verified
- Jan 2026
- First submitted
- 19 Jan 2026
- Last updated
- 30 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-Guided Nerve Hydrodissection With 5% Dextrose in Carpal Tunnel Syndrome: A Prospective Study
- ClinicalTrials.gov ID
- NCT07371221
- Acronym / sponsor ID
- 2024-KAEK-09
- Conditions
- Carpal Tunnel Syndrome (CTS)
- Keywords
- carpal tunnel syndrome, hydrodissection, Microvascular imaging, ultrasound guided injection, median nerve
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 37 participants (actual)
- Lead sponsor
- Dr. Nafiz Korez Sincan State HospitalOther government
- Study start
- 17 Jun 2024 (actual)
- Primary completion
- 26 Jun 2025 (actual)
- Study completion
- 26 Jun 2025 (actual)
- First posted
- 27 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the clinical and ultrasonographic outcomes of ultrasound-guided median nerve hydrodissection with 5% dextrose in patients with mild and moderate carpal tunnel syndrome.
The main questions it aims to answer are:
- Does ultrasound-guided dextrose hydrodissection improve pain and functional status in patients with carpal tunnel syndrome?
- Does this procedure lead to changes in ultrasonographic parameters of the median nerve?
- Is ultrasound-guided dextrose hydrodissection a safe procedure in this patient population?
Participants will:
- Undergo a single session of ultrasound-guided median nerve hydrodissection with 5% dextrose
- Be evaluated before the procedure and at 1-month and 3-month follow-up visits using clinical outcome measures and ultrasound assessment
- Be monitored for any procedure-related adverse events
Detailed description
Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy of the upper extremity and is caused by compression of the median nerve within the carpal tunnel. Conservative treatment options are commonly preferred in patients with mild to moderate CTS. Ultrasound-guided interventions have gained increasing attention due to their ability to provide real-time visualization of anatomical structures and improve procedural accuracy and safety.
Ultrasound-guided median nerve hydrodissection is a minimally invasive technique that aims to mechanically separate the median nerve from surrounding tissues within the carpal tunnel, potentially reducing nerve compression and improving nerve mobility. The use of 5% dextrose solution has been suggested to provide both mechanical and potential neuromodulatory effects, which may contribute to symptom relief.
In this prospective study, patients diagnosed with mild and moderate CTS undergo ultrasound-guided median nerve hydrodissection using 5% dextrose. All procedures are performed under aseptic conditions by experienced physicians trained in ultrasound-guided interventions. A high-frequency linear ultrasound transducer is used to visualize the median nerve and surrounding anatomical structures at the level of the carpal tunnel. Hydrodissection is performed using an in-plane technique, which allows for continuous visualization of the needle and injectate during the procedure.
Participants receive a single-session ultrasound-guided hydrodissection, during which the injectate is administered to separate the median nerve from adjacent connective tissues. The procedure is conducted according to a standardized protocol to ensure consistency across all participants.
Clinical and ultrasonographic assessments are performed at baseline, and at 1-month and 3-month follow-up visits after the ultrasound-guided injection. Patients are monitored for any procedure-related adverse events throughout the study period. The study aims to evaluate changes in clinical symptoms and ultrasound findings following the intervention, as well as to assess the safety profile of ultrasound-guided dextrose hydrodissection in patients with mild and moderate CTS.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a single-arm, prospective, non-randomized interventional study. All participants receive ultrasound-guided median nerve hydrodissection with 5% dextrose, and outcomes are measured before and after the intervention.
| Arm | Type | Receives |
|---|---|---|
| Ultrasound-Guided Dextrose Median Nerve Hydrodissection | Experimental | Procedure: Ultrasound-Guided Median Nerve Hydrodissection with 5% DextroseParticipants in this arm undergo a single session of ultrasound-guided median nerve hydrodissection using 5% dextrose solution. The procedure is performed under aseptic conditions with real-time ultrasound guidance to visualize the median nerve and surrounding anatomical structures within the carpal tunnel. The injectate is administered to mechanically separate the median nerve from adjacent tissues. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age between 18 and 65 years
- Electrophysiologically confirmed mild to moderate CTS on electroneuromyography (ENMG)
- Paresthesia or dysesthesia that worsens at night or with repetitive wrist movement
- Presence of at least one of the following clinical findings:
- Pain intensity of ≥3 on the Visual Analog Scale (VAS)
Key exclusion criteria (9 listed)
- Previous carpal tunnel surgery
- Severe CTS on ENMG
- Polyneuropathy
- Pregnancy
- Injections in the same area within the last 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound-Guided Median Nerve Hydrodissection with 5% DextroseThis intervention consists of a single-session ultrasound-guided hydrodissection of the median nerve using 5% dextrose solution in patients with mild and moderate carpal tunnel syndrome. The procedure is performed under aseptic conditions by trained physicians using a high-frequency linear ultrasound transducer. Real-time in-plane imaging is used to visualize the median nerve and surrounding structures, and the injectate is administered via an ulnar approach to mechanically separate the median nerve from adjacent connective tissues within the carpal tunnel. Participants are monitored for any procedure-related adverse events during and after the intervention. | Procedure or surgery | Ultrasound-Guided Dextrose Median Nerve Hydrodissection |
Primary outcome
Change in Visual Analog Scale
Time frame: Baseline, 1 month and 3 months
The severity of pain in the fingers over the past week was measured using a 10-cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
3 secondary outcomes
Change in Vascularity Index of the Median Nerve
Time frame: Baseline, 1 month and 3 months
Change in median nerve cross-sectional area
Time frame: Baseline, 1 month and 3 months
Change in Boston Carpal Tunnel Questionnaire
Time frame: Baseline, 1 month and 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2026.
Related trials for Carpal Tunnel Syndrome (CTS)
Not yet recruitingObservational study
Postural Control and Balance Performance in Patients With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Postural Assessment
Recruiting
Comparison of Wrist Splint Positions in Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Peripheral Neuropathies
Recruiting
Effects of Repetitive Peripheral Magnetic Stimulation(rPMS) on CTS(Carpal Tunnel Syndrome)
Carpal Tunnel Syndrome (CTS)
Recruiting
Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-burn Patients Presented With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS) Post-burn
Not yet recruiting
Effect of Progressive Gamified Motor Rehabilitation After Carpal Tunnel Release
Carpal Tunnel Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Suheyla Dal Erdogan, Medical Doctor study chair
Dr. Nafiz Korez Sincan State Hospital
Sevgi Esra Ozdemir Tekes principal investigator
Dr. Nafiz Korez Sincan State Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound-Guided Median Nerve Hydrodissection with 5% Dextrose in people with Carpal Tunnel Syndrome (CTS), run by Dr. Nafiz Korez Sincan State Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Visual Analog Scale (time frame: Baseline, 1 month and 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.